Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Onvansertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cardiff Oncology Updates Onvansertib mCRC Phase 2 Data at ASCO
    Cardiff Oncology Updates Onvansertib mCRC Phase 2 Data at ASCO

    21 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7198562

    FIRSTWORD PHARMA
    21 Apr 2026
    Share Share
    Cardiff Oncology Unveils Onvansertib Data With Her2-Targeted ADC
    Cardiff Oncology Unveils Onvansertib Data With Her2-Targeted ADC

    19 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7187992

    FIRSTWORD PHARMA
    19 Apr 2026
    Share Share
    Cardiff Oncology Hosts KOL Talk On RAS+ Metastatic CRC Cancer
    Cardiff Oncology Hosts KOL Talk On RAS+ Metastatic CRC Cancer

    20 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/20/3259664/0/en/Cardiff-Oncology-to-Host-Key-Opinion-Leader-Discussion-Focusing-on-First-Line-RAS-mutated-Metastatic-Colorectal-Cancer.html

    GLOBENEWSWIRE
    20 Mar 2026
    Share Share
    Cardiff Oncology to Host Key Opinion Leader Discussion
    Cardiff Oncology to Host Key Opinion Leader Discussion

    20 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/20/3259664/0/en/Cardiff-Oncology-to-Host-Key-Opinion-Leader-Discussion-Focusing-on-First-Line-RAS-mutated-Metastatic-Colorectal-Cancer.html

    GLOBENEWSWIRE
    20 Mar 2026
    Share Share
    Cardiff Oncology To Showcase Onvansertib Preclinical Data
    Cardiff Oncology To Showcase Onvansertib Preclinical Data

    19 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/19/3258838/0/en/Cardiff-Oncology-to-Present-Preclinical-Data-with-Highly-Specific-PLK1-Inhibitor-Onvansertib-at-the-2026-AACR-Annual-Meeting.html

    GLOBENEWSWIRE
    19 Mar 2026
    Share Share
    Cardiff Oncology Releases 2025 Results And Business Update
    Cardiff Oncology Releases 2025 Results And Business Update

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3244087/0/en/Cardiff-Oncology-Reports-Full-Year-2025-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.